On or around 10/10/2017 (Ongoing date of last review)
Filing Date: February 17, 2017
According to the Complaint, it is allegedDefendants have asked Transgenomic shareholders to vote in favor of this extremely complex Proposed Transaction by disseminating a materially incomplete and misleading Proxy Statement (the “Proxy”), in violation of Sections 14(a) and 20(a) of the Exchange Act. In particular, the Proxy contains materially incomplete and misleading information concerning: (i) the terms and details surrounding discussions regarding alternative strategic proposals the Company received from other parties; (ii) financial projections for the Company and Precipio; and (iii) the valuation analyses performed by the Company’s financial advisor, Craig-Hallum Capital Group LLC (“Craig-Hallum”), in support of its so-called “fairness opinion.”
On August 9, 2017, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended complaint on August 25.
Company & Securities Information
Defendant: Transgenomic, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: TBIO
Company Market: OTC-BB
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Jesse Campbell, et al. v. Transgenomic, Inc., et al.